{
    "clinical_study": {
        "@rank": "53477", 
        "arm_group": [
            {
                "arm_group_label": "Sofosbuvir+RBV 12 weeks TN", 
                "arm_group_type": "Experimental", 
                "description": "Treatment naive (TN) participants coinfected with HIV-1 and genotypes 2 and 3 HCV infection will receive sofosbuvir plus RBV for 12 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 24 weeks TE", 
                "arm_group_type": "Experimental", 
                "description": "Treatment experienced (TE) participants coinfected with HIV-1 and genotypes 2 and 3 HCV infection will receive sofosbuvir plus RBV for 24 weeks."
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 24 weeks TN", 
                "arm_group_type": "Experimental", 
                "description": "Treatment naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive sofosbuvir plus RBV for 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (GS-7977) plus\n      ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are\n      co-infected with HIV-1."
        }, 
        "brief_title": "A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatitis C,", 
            "Human Immunodeficiency Virus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Immunologic Deficiency Syndromes", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following inclusion criteria to be eligible for\n        participation in this study.\n\n          1. Willing and able to provide written informed consent\n\n          2. Male or female, age \u2265 18 years with chronic HCV and HIV-1 infection\n\n          3. HCV RNA > 1 x 104 IU/mL at Screening\n\n          4. Infection with HCV genotype 1, 2 or 3 as determined at Screening\n\n          5. HIV-1 infection confirmed with positive ELISA or Western blot at Screening\n\n          6. The subject's medical records must be sufficient to be categorized on IFN eligibility\n             or prior treatment history with PEG/RBV.\n\n          7. Confirmation of chronic HCV infection\n\n          8. Ability to determine presence/absence of cirrhosis.\n\n          9. HIV antiretroviral therapy (ARV) criteria of one of the following:\n\n               -  ARV untreated with a CD4 T-cell count >500 cells/mm3\n\n               -  On a stable, protocol-approved, ARV for >8 weeks prior to Screening with a CD4\n                  T-cell count >200 cells/mm3 and a documented undetectable plasma HIV-1 RNA level\n                  for \u2265 8 weeks preceding the Screening visit\n\n         10. Approved HIV antiretroviral medications based on drug interaction studies\n\n         11. Subject has not been treated with any investigational drug or device within 30 days\n             of the Screening visit\n\n         12. Females if confirmed that she is not pregnant or nursing of non-childbearing\n             potential or of childbearing potential but has a negative serum pregnancy test at\n             screening and agrees to use protocol approved method of birth control from screening\n             through 6 months after the last dose of RBV\n\n         13. Male subjects who agree to consistently and correctly use a condom while their female\n             partner agrees to use protocol approved method of birth control from screening\n             through 7 months after the last dose of RBV\n\n         14. Subject must be of generally good health as determined by the Investigator.\n\n         15. Liver imaging within 6 months of Baseline/Day 1 is required in cirrhotic patients\n             only, to exclude hepatocellular carcinoma (HCC)\n\n        Exclusion Criteria:\n\n        Subjects who meet any of the following exclusion criteria are not to be enrolled in this\n        study.\n\n          1. Non-genotype 1/2/3 or mixed genotype at Screening\n\n          2. Genotype 1 with prior treatment for HCV\n\n          3. Poor control with ARV regimen\n\n          4. Prior exposure to a direct-acting antiviral targeting the HCV nonstructural protein\n             (NS)5B polymerase\n\n          5. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease,\n             \u03b11 antitrypsin deficiency, cholangitis)\n\n          6. A new AIDS-defining condition diagnosed within 30 days prior to screening\n\n          7. Active, serious infection (other than HIV or HCV) requiring parenteral antibiotics,\n             antivirals or antifungals within 30 days prior to Baseline\n\n          8. Infection with hepatitis B virus (HBV)\n\n          9. Contraindication to RBV therapy\n\n         10. Chronic use of systemically administered immunosuppressive agents (e.g., prednisone\n             equivalent > 10 mg/day)\n\n         11. History of solid organ transplantation or malignancy diagnosed or treated within 5\n             years\n\n         12. Current or prior history of clinical hepatic decompensation or other significant\n             gastrointestinal disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667731", 
            "org_study_id": "GS-US-334-0123"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 12 weeks TN", 
                    "Sofosbuvir+RBV 24 weeks TE", 
                    "Sofosbuvir+RBV 24 weeks TN"
                ], 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "Sovaldi\u00ae"
                ]
            }, 
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 12 weeks TN", 
                    "Sofosbuvir+RBV 24 weeks TE", 
                    "Sofosbuvir+RBV 24 weeks TN"
                ], 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis C", 
            "Chronic", 
            "HCV", 
            "HIV", 
            "Human Immunodeficiency Virus", 
            "Co-Infected"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coronado", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lutherville", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington DC", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hillsborough", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Fe", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Allentown", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Anuj Gaggar", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667731"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 and SVR24 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 4 weeks and 24 weeks following the last dose of study drug, respectively.", 
                "measure": "Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4 and 24"
            }, 
            {
                "description": "Virologic failure is defined as either:\nVirologic breakthrough (participant achieved undetectable HCV RNA levels during treatment but subsequently had detectable HCV RNA while continuing treatment), or\nNon-response (HCV RNA persistently \u2265 25 IU/mL through 8 weeks of treatment ), or\nVirologic relapse (HCV RNA \u2265 25 IU/mL during the posttreatment period having achieved HCV RNA < 25 IU/mL at end of treatment), or\nRebound (> 1 log10IU/mLincrease in HCV RNA from nadir while on treatment).", 
                "measure": "Proportion of participants with on-treatment virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }, 
            {
                "measure": "HCV RNA change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 8"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}